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PriInary cutaneous CD30 (Ki-l)+ large cell lymphoma 
(IGL) and lymphomatoid papulosis (LyP) type A are 
collectively termed as primary cutaneous CD30-pos-
itive IYlnphoproliferative disorders. We exalllined 
, the cytokine profile of skin-infiltrating cells and the 
therapeutic efficacy of recombinant interferon-l' 
(rIFN-l') in primary cutaneous KiL and LyP type A . By 
t r everse transcriptase-polymerase chain reaction, 
mRN"As for interleukin-4 (IL-4) and IL-I0 were de-
I t ected in the dernlis of skin lesions in all cases (three 
cas es ofKiL and four cases ofLyP). In addition, tissue 
frOIn one KiL patient transcribed IL-2 and IFN-1' 
messages, and one LyP patient showed IL-2 mRNA. 
In contrast, normal skin from ten healthy donors 
contained mRNA for IL-2 or IFN-l', or both, but not 
for IL-4. Before the therapeutic trial of rIFN-l', the 
response of skin lesions was assessed by a predictive 
skin. test with local injection of rIFN-l' (0.5 X 10(' 
J apan Reference Units ORU; 1 JRU roughly corre-
sponds to 4 NIH units]) for 3 consecutive days in two 
KiL and two LyP patients. Numbers of skin-infiltrat-
P rimary c utaneous C D30-positivc Iympho pro liferativc di sorde rs (Willem ze and Beljaards, 1993) fo rm a sp ec-trum of c utaneous lymphoma ill which m ost o r all of the an apl astic, large, som e tim cs R ecd-S tc rnberg-like cells express C D30 (IG -"1 anti gen) (Wille mze eI ai, 
1983 ; Ka din el ai , '1985; Kadin, 1990; Da vis el ai, 1992; Willcm ze 
and B e ljaards, 1993; Willemze, 1995) . D espi te the o bserva tio n that 
some types of lympho mas in this g ro up have a comm o n ac ti vated 
T- celJ o rigin (Kadin, 1985; Da vis el ai , '1992), the bio logic beha vio r 
of atypical/tumo r cells and thus the clinical course arc quite 
varia ble. Lymph o m ato id papul osis (LyP) represcnts a benign ex-
treme (Maca ulay, 1968) , w hereas high-g rade C D 30 + large cc ll 
lymphomas (KiL ) are aggress ive (Wille m ze and Beljaa rcls, 1993 ; 
Cucco el ai , '1994) . LyP is a chronic, recurrent, se lf-h ealing papu-
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ing CD30 + cells were decreased, and transcription of 
InRNA for IL- 4 and IL-10 was downregulated after 
the skin test in one KiL and two LyP cases. One KiL 
patient showed no histologic response or change in 
mRNA expression. In the therapeutic trial, rIFN-1' 
(total doses of 1.2-4.0 x 10' JRU) was adlllinistered 
intravenously (n = 2) or locally (n = 2). In three 
patients who responded to the skin test, the lesions 
were objectively improved and the numbers of skin-
infiltrating CD30+ cells were markedly decreased 
after the therapeutic trial. No improvement was ob-
served in one KiL patient who did not respond to the 
skin test. These findings suggest that the skin-infil-
trating CD30+ cells in KiL and LyP have a Th2 
cytokine profile and raise the possibility that the 
adlllinistration of rIFN-l' improves the conditions by 
inhibiting cytokine mRNA transcription and prolif-
eration of CD30+ cells. K ey words: Ki-1+ IYlllphoma/ 
IJIII/piro ilia to i d pap IIlos is / e ll (a,lIeo liS T-cell IYlllphollla / a IW-
plastic large cell Iymphollla. ] Illvest D el'llw(ol 107:827-
832, 1996 
lo necrotic or papulollodular skin disease (Macaulay, 1968) , and 
o nly type A is chara cteri zed by CD3 0 positivity (W ill em ze el ai, 
1983). Dcspite its m alignan t histo logic appearance, less than 5% of 
cases of LyP precede or fo llow a malignant lympho m a, usually 
m ycos is fungoides, Hodgkin' s disease , o r IGL (Be ljaards and Wil-
lelllze, 1992 ; Davis el ai, 1992) . Primary cutaneous and primal)' 
nodal KiL are distinct clinical entities that have iden tica l m o rpho-
logic fea tures (de Bruin el ai, 1993) . Primary nodal KiL is COITlmo n 
in childhood and adolescence and has a less favorable progn osis (de 
Bruin c{ (/1 , 1993 ). Tn con trast to primary nodal Ki L, pl'im31), 
cu tancous IGL generally occurs in adul ts , o ften shows p artia l or 
evcn complete spontan eous regress io n , and rarely develo ps ex tra-
cu ta ncous les ions (C han cl ai, 1989; Banerjee Cf ai, / 99 1; Beljaards 
el ai, 1993; Wille mze and Be ljaards, 1993 ) . T he t(2;5) chrom o-
som al transl ocation , w hich is hig hly assoc iated w ith p rimary nodal 
KiL, is not a common fea ture o f primary cutaneons KiL (DeCoteau 
cl ai, 1996) . Mos t of the repo rted cases of primary cu taneous KiL 
ha ve had a f.1 vorable progn osis , with a 4- year surviva l rate o f 90'X) 
(Belj aards el ai , 1989; C han cl ai, 1989; Kaudewitz ef ai, 1989; 
Banerjee el ai , 199 1; Be ljaards el ai, 1993; Willem ze and Beljaa rcl s, 
1993). T he re fore , aggressive treatment is pro bably unnecessat), fo r 
this type of cutaneous lympho m a (Be ljaards ef ai, 1993 ). 
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On th e basis of di stin c t patterns of cytokine secretion, T -helper 
ce ll popul a tions are categorized in both mke and human s into the 
T h l ce ll subset, secreting inte rl eukin-2 (IL-2) and interferon-y 
(l FN-y), and the T h 2 ce ll subset, producin g lL-4, IL-5, and LL-1 0 
(Mosm ann and Coli:illan , 1989; Romagnani, 1991; Paul and Seder, 
1994). T hese two types of T cell s and the cytokines derived from 
th em coun te rregulate the bio logic b eh av ior of each oth e r (M os-
mann and Coffillan, 1989). T h ese subse ts are the important com-
po n en ts of T-cell respon ses in severa l di seases (Karpus et al. 1992; 
C leric i et ai , 1993; Rapoport et ai, 1993) . T he administration ofTh1 
cytokin es such as I FN- y is thus expected to improve disorders in 
w hich T h 2 cells are p athogenic by coun teractin g T h 2 cell s and 
activatin g T hl cell s (Boguniewicz ct ai, 1990; Fushimi et ai, 1996). 
T his article d escribes th e T h2 n ature of skin-infiltrating. atypica l 
ce ll s in primary cutan eo us CD30-posit ive lympho pro liferative di s-
o rders. In three of four cases w ith prim ary cutaneo us KiL o r LyP 
type A. the loca l or intra venous injec tion of recombinant lFN-y 
(r1 FN-y) improved th e condition s and sim ultaneous ly downregu-
lated T h 2 cytokine mRNA tran scription in skin-infi ltra ting cells . 
MATERIALS AND METHODS 
Patients T hree patients with primnl'y cutaneo us KiL (cases 1 to 3; three 
maJes. mean age ± SO: 79.7 ± 4.9) and fo ur with LyP type A (c"ses 4 to 7; 
three males and Olle fema le, age = 52.3 ± 28.2) we re diagnosed on the basis 
of criteria reported previously (Macaulay, 1968; WiJlemze cl nl, 1983; 
Willelll zc and Beljaards . 1993). T he skin lesions consisted of multiple 
tumors in cases 1 and 3, a soli tary tumor in case 2, and se lf-hea ling multiple 
papules in cases 4 to 7. Extmcutaneous dissemination of the disease or other 
types of Iympho proliferative di sease were nO[ dern onstrated. All paticnts 
we rc scronegative for hUl11 an T-cell Iymphotrophic virus type I antibod ies. 
T he Southern blotting ana lysis of DNA from les ional skin (l kuta er nl, 1985) 
of two patients with KiL (cases 1 and 2) reve" led rca rranged nongermline 
bands with the usc of a DNA probe fo r a constant region ofT-ceLl receptor 
(3 chain (C(31) . No clonal rearrangement was de l11onstr:.ted ill an y LyP cases 
examilled. No p"tients had received chemotherapy or radiation or local 
trea tment of rhe skin lesions for at least 1 month before the study. Skin 
les ions of all KiL cases had been growing until this study and had nOt 
regressed spontaneously. Each lesion ofLyP regressed spontaneously within 
a few ~eeks ; i.e., it started as a small red papule that en larged, then eroded, 
and fina ll y hea led. leaving a depigmcllted spot. T reatments alld all exami-
11:1t1 0 I1 S in this study were pcrforrn cd after in forill cd consent was obta ined. 
Histologic and I1nmllnohistochcmical Stndics Skin biopsy spec i-
mens were obtained from all patients. Half of the specimen waS fixed in 10'1. 
forma ldehyde solu tion and embedded ill paraffin fo r light microscopy. T he 
other half was fi xed ill periodate-Iys inc-parafonnaldehyde solution. cryo-
sectioned. and innllunophenotyped with the three-step ill1l11unoperoxidase 
technique (Tokura el nl. 1986). The monoclonal antibodies used in this 
stud y included 'lll ti-CD3 , -CD4 . -C DS, -CD20, - CD25, -CD45RA , and 
-human leukocyte antigen (HLA)-DR (necton Dickinson , Mountain View, 
CA); anti-CD30 and -CD45 RO (Dakopatts, Glostrup , Denmark) ; and 
anti-CD71 (Ortho Diagnostics Systems, R aritan. NJ) . Les ions were consid-
ered positive for the lllarker if 111 0re than 50':1\, of Inrge atypical cells were 
stained. 
Reverse Transeriptasc Polymcrase Chain Reaction (PCR) Analysis 
of Cytolcinc 1l1RNA Expression Spccinlcns \-"ere take n fro l11 tll1nors in 
KiL and papules ill LyP. Skin samples fi'om the trun k of ten hea lthy 
voluntee rs (four males and six fema les. mean age ± SO: 26.3 ± 9.2) served 
as controls. Dermal portions of the skin were resected from biopsy 
specimens under a microscope. Tota l RNA was extracted fro m the samples 
as descri bed prev iously (Chomczynski and S"cchi , 1987). First-strand 
eDNA was reverse transcribed using each RNA sample and was amplified 
by PC lt (Saiki ('1 ti l, 1988) as described previously (Yagi el ti l, 1996) . T he 
primers used were as follows: IL-2. 5' primer ATGTAC AGGATG-
CAACTCCTGTCTT, 3' primer GTCAGTGTTGAGATGATGCTTT-
GAC; 1L-4, 5' primer ATGGGTCTCACCTCCCAACTGCT, 3' primer 
CGAACACTTTGAATATTTCTCTCTCAT; IL- 5, 5' primer GCTTCT-
GCATTTGAGTTTGCTAGCT, 3' primer TGGCCGTCAATGTATT-
T CTTTATTAAG; IL- IO, ~ primer ATCAGCTGGACAACTT-
GTTG . 3' primer GTCCTAGAGTCTATAG AGTC; IFN-y. S' primer 
ATGAAATATACAAGTTATATCTTGGCTTT, 3' primer GATGCTCT-
TCGACCTCGAAACAGCAT; and {3-actin , 5' primer TGACGGGGT-
CACCCACACT GTGCCCATCTA , 3' primer CTAGA AGC ATTGCG-
GTGGACGAT GGAGGG . 
T he PC R products and DNA molecular-weight marker VI (Bochringer 
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Mannheim GmbH, Manllheim, Germany) were separated in 2% agarose 
gels. The gel was stai ned with 1 Jl.g ethidium bromide per ml , and amplified 
DNA bands were visualized with all ultraviolet transilluminator. The 
photographed bands of reverse transcriptase PCR products were scanned 
with a computer sc"nner OX-330M; Sharp , Osaka, J apan). The densi ty of 
the scanned band WaS quantified by image-analyzing softwarc (NIH Image). 
T he intensi ty of cytokinc mRNA exprcss ion was estimated by calculating 
the relative density of cytokine PC R bands against (3-actin in the same 
sample. 
Evaluation of Thcrapeutic Effccts of rIFN-1' T he administration of 
r1FN-y has been approved by the Ministry of Health and Welfare in J apan 
fo r the treatment of patients with cutancous T-ce ll lymphoma (CTCL). 
Two X 10" J apan R eferencc Units ORU ; 1 JRU ro ughly corresponds to 4 
NIH units) ofrlFN-y (I3 iogamma; Maruho Co ., Osaka,Japan, and Suntory 
Ltd .• Osaka, Japan; specific activity 5 X 10" J RU per mg of protein) was 
ad ministrated intravenously in cases 1 (daily, 11 times) and 4 (daily, 20 
times), and loca ll y in Cases 2 (dail y, seven times) and 5 (twice a week, six 
times) . The clinical effi cacy of r1FN-y administration was evaluatcd by 
comparing the severity of skin lesions before and afte r the trea tment. The 
severity ofKiL was expressed as the vo lume of each tumor. Eruptions ofLyP 
wax and wane (Macaulay, 1968). T he severi ty was thus assessed by 
enumerating eruptions and scoring the clinical appearance of each eruption 
(1 = mildly erythema to us; 2 = moderatel y erythemato us and p"pular; 3 = 
severel y erythematous and papular) in three randomly selected areas (each 
app roximately 100 cm' ) that initially contained at least fi ve papules, and was 
expressed as the sum of the number of eruptions with the same clinical 
appearance multiplied by its score. T hercfore , if one arca contained thrce 
severely and fi ve moderately erythematous and papul"r eruptions. the 
severity was (3 X 3) + (5 X 2) = 19. The assessment was performed every 
7 dafter rIFN-y administration. 
RESULTS 
Histologic and Immunohistochemical Findings of the KiL 
and LyP Skin Lesions Biopsy specimens fro m the lesional skin 
reveale d a d en se lymphoid infiltrate in the d ermis in all cases. T h e 
infiltrate in KiL was composed exclu sive ly of large ce ll s with 
abundant cytoplasm and a pleomorphic nucleus. In LyP, such large 
atypical ce ll s were mixed with a m o derate number of inflammatory 
cells, in partic ula r n e utrophil s and eosino phils. R esults of the 
immuno histochemical stainin g are summarized in Table I. In all 
cases examined, large atypical cell s w ere positive for CD3, CD30, 
CD25, CD45RO , CD71, and HLA-DR. On th e othe r hand , CD8, 
CD20, o r C D45RA w e re not 'expressed in any case. T h erefore 
an aplastic large cell s in these cases showed the morphology and 
expression pattern of surface antigen s typ ically o b served in KiL and 
LyP type A (Tokura el nl, 1986; Beljaards el ai, 1989, 1993; 
Kaudewitz ct ai, 1989; Parks CI ai , 1992) . 
Th2 Cytokine mRNA Expression by Dermal Infiltrating 
Cells Before exploring the cytokine profil e of skin-infdtrating 
cells in KiL and LyP, w e exam ined the background e xpress ion of 
cytokine mRNA in normal dermis (Table II). N o rmal dermal 
sampl es f1:om ten h ealthy do n ors contained mRNA for e ither lL-2 
or IFN-y, or b oth. On the othe r hand ; mRNA for IL-4 or IL-5 was 
not detec te d ill any sample . lL-lO mRNA was expressed in fiv e 
samples rega rdless of the expression profile of o the r cytokines . 
Figure 1 summarizes the mRNA expression for cytokines in th e 
d ermal p ortion of biopsy sp ecime ns in seven cases. AU samples used 
in these experiments gave comparable amplifi ed bands w ith the 
/3-actin primers, indicating integrity of RNA. All bio psy specimens 
from the untrea te d lesion s contain ed mRN A transctipts for both 
IL-4 and lL-10. IL-5 mRNA was de tected in one case (case 3). 
Whereas five of seven cases (cases 1, 3, 5, 6 , and 7) did not 
tran scribe mRNA for IL-2 o r l FN-y, dermal p o rtions conta ined 
mRNA for IL-2 in cases 2 and 4 and also l FN-y in case 2, in 
addition to simultan eou s tra;lsc ription ofmRNA for T h 2 cytokin es . 
Decrease in CD30 + Cell Number and Th2 Cytokine mRNA 
Transcripts by Local Injection of rIFN-y B efore the treat-
m ent, iml11un o histoche mica l and cytokine mRNA profil es were 
examin ed be fore and after the inj ection of rIFN-y into lesions of 
the trunk in cases 1 , 4, and 5 and in a solitary tumor of the n eck in 
case 2, for 3 consecutive days (2.5 X 10" JRU/cm 2 of skin surface, 
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Table I. Immullophellotype of Large Atypical Cellsfl 
A ntigen 
Cases C03 C04 C08 C020 C025 C D30 CO~5RA C045RO C071 HLA-OR 
JGL" 
1 + + + + + + + 
2 + + + + + + 
3 + + + + + + + 
Lypr (type A) 
4 + + + + + + + 
5 + + + + + + + 
6 + + + NO" NO + + 
7 + + + + + + + 
/J Les io n s were considered positive (+ ) if morc than 50%, of large ;)typi cai cells werc stained. 
" IGL. prim:lry curanCOIiS C D30 + lnrgc cell lympholll :1 . 
~ LyP. lYl11phoma lo id papulosis. 
II ND ,. DOt dOlle . 
once a day) . Whereas changes in clinical appearance of the 
eruptions w e re not overt in any case after a tota l dose of 1.5 X 10(' 
JRU, the numbe r of skin-infiltrating cells was redu ced in response 
to rIFN -I' in cases 1, 4, and 5 (Table III). Although both CD3 + 
and CD30 + cells were dramatica lly decreased in number, the effect 
of rIFN -I' was more apparent on CD30 than on C03 expression , as 
assessed by the ratio of C030 + to CD3 + cells (C030IC03). On 
the other hand, ne ither the numbe r of skin-infiltratin g cells nor the 
ratio of C030lC03 was changed in case 2 . The density of each 
peR band was quantifi ed, and the intensity ofmRN A expression in 
indivi dual patients was expressed as the relative density of cytokine 
bands aga inst the f3-actin band for comparison between the sam-
ples . T he de nsities of IL-4 PC R pro ducts were decreased , and the 
signal s for rL-10 mRNA disappeared after the injectio l] in cases 1 , 
4, and 5 (Fig 1). This selective eff:ect on cytokine transcription was 
remarkable in case 4, in which injections of rIFN-1' downregulated 
rnRNA for Th2 cytokines and simultaneously upregul ated mRNA 
for IL-2 and IFN-I'. The densities of bands for IL-4. IL-l0, IL-2, 
and IFN-I' were at comparable levels before and after the injection 
in case 2 (data for post-treatment not shown) , reflecting the 
immunohistochemical analysis . T hese fi ndings indicate that a de-
crease in the CD30/C03 value an d disappearance ofTh2 cytokine 
messages were critica lly re lated to the biologic activities of rlFN-I'. 
More important, as described in the next section , this skin test 
predicted the clinical efficacy of r1FN-I'. 
Therapcutic Effeets of rIFN-y Recombinant IFN-I' was ad-
ministered e ithe r intravenou sly or locally in the patients with IGL 
and LyP w ho had predicti ve skin tests. Three cases (cases 1, 4, and 
5) responded well to rIFN-1' (Fig 2); the severity scores after 
rIFN-y administration in three lesio ns in each case were reduced to 
Table II. IL-2 and IFN-I', But Neither IL-4 Nor IL-5 
Cy1:okillc rnRNAs, Are Detected in Normal Dermis" 
Indjviduol IL-2 IL-4 IL-5 IL- I0 IFN-y 
1 + + 
2 + + 
3 + + + 
4 + + 
5 + + + 
6 + + 
7 + 
8 + .+ 
I) + + 
10 + + 
Nu mber of positive 
samples 8 0 0 5 8 
" R..N A _ was extracted fi·onl the dcrl11;11 portion of sk in hiopsy specimens frolll fe ll 
healthy dOllo rs and :lIw lyzcd by reverse tl'~ll scrip t;]sc-PCR. +, detect'lhlc level by 
reverse tr;l l1 scriprasc-PCR; - . below the detectable level. 
42.0 :!: 6.0%. 17.7 :!: 4.7%, and 33.3 :!: 11.1 % (mean :!: SO) of 
pre-treatment values, respectively. Refl ecti ng the therapeutic efFect 
of rlFN-I', the number of skin- infiltra ting cells and the CD30lC03 
ra tio were red uced markedly after the treatment in cases I , 4, and 
5 (Table III; Fig 3). Afte r discontinuation of rIFN-I', the severity 
score re turned to the pretreatment level within severa l weeks. In 
case 2, on the con trary, the volume of tumor was not decreased and 
histopatho logic findings were n ot changed by intralesional injec-
tions. Live r and renal function and blood e lectrolyte levels had been 
norma l in all patients during the treatment and 6-month follow-up . 
DISCUSSION 
T his study indicates that T h2 cytokines are produced by CD30 + 
anaplastic large cells. Two findings valida te this notion. First, 
dermis infiltrated by CD4 + C03(rr a typical cells always expressed 
mRNA for T h2 cytokines . T his was not necessarily the case in 
normal samples. Second , the local injection of rIFN-I', w hich 
coun teracts T h2 cells preferentially, reduced the number ofCD30 + 
cells and simultan eously inhibited mRNA expression for Th2 
cytokines. A literature search reveals no studies concerning the 
cytokine profile of skin-in fi ltrating atyp ica l ce lls in primary cuta-
KiL 
Case 1 Case 2 Case 3 
Treatment -
Cylokines 
~-actin 
IL-2 
IL-4 
IL-5 
IL-IO 
IFN-y 
++ + 
LyP 
Case 4 Case 5 Case 6 Case 7 
+ ++ 
+++ +++ 
--
+ + 
--+ 
Figure 1. Th2 cytokine mRNA expression b y dermal infi ltrating 
cells ofKiL and LyP is downregulated b y predictive, local injection 
of rIFN-y_ Messenger RNAs were extracted &0111 lesional dermis and 
ollo lyzed by reverse transcript",c PCR . III cases I , 2. 4. and 5. r1FN-y at 
2.5 X 10· JRU /cm2 of skin SurfiI CC , once a do l' . was injected into lesions fo r 
3 consecutive days, and skill biopsy specimcns were taken before (- ) and 
after (r1FN-y) injections. The intells ity ofmRNA expression was calculated 
in eoch somple according to the fo llowing formula: (densiry of cytokinc 
band) / (dcnsity of {3-actin band of the same sample). - . below the detect-
ab le le vel; +, detectable level: + +. density of th e band \vas Inore th~ln 
,twice os strong os the r1FN-')'-trcotcd or non-treated pair. 
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Table III . The Ameliorating Effect of Skin Test and 
Treatment With rIFN-')' Is More Apparent 011 CD30+ 
Cells Than on CD3+ Cells in, the Lesional Skin" 
Trcatnlcnt: 
Skin T est: Number of CD3 + Number ofCD3 + 
Cells
" 
(CD30/CD3), Ce ll s (CD30/CD3) 
Cases Before After Before After 
1 548 (0.94) 263 (0.55) 638 (0 .96) 71 (0.16) 
2 775 (0.99) 736 (0.96) 775 (0.99) 794 (0.97) 
4 242 (0.9.1) 139 (0 .47) 252 (0.93) 31 (0.04) 
5 377 (0.82) 122 (0.32) 336 (0.88) 55 (0.14) 
" ImTllun o hi stochemical study of sk in biopsy speci m ens taken before lind a fte r the 
predictive skin tcst (inrr<l icsionai injccrjoll. 2.S X 10" Jlt.U/cm2 of skin sllrf.1l:c. 3 
consecu tive day); , o llce n day) ;"Ind treatment (IOCcll or ill(T:l VCIlO U S inj ection). 
h The 1:0[:11 number of positi ve cells in th ree 400 X ma g-ni ficd field s in the center of 
cel l infi ltration was cOLIn ted. 
( Ratio of C D30 -r [0 C D3 + cells in rhe same lesion. 
neous CD30 + Iymphopro li fe rative disorde rs, but recent reports 
have demonstrated the association between CD30 expression and 
the production of Th2 cytokines in both CD4 + and CD8 + cell s. 
AlIerg!,!ll-specific CD4 +CD30-1- T cells are stim ulated to produce 
T h2 cytokilles in the circulation of atopic patien ts after allergen 
Figure 2. ~kin lesions of KiL and LyP arc improved by treatment 
:with rIFN-y. Clinical pictures of case 1 (101'). case 4 (m iddle). and case 5 
(bollolll) before (left) and after ("ight) treatment with r1FN-y show that the 
size of a tumor in KiL and the number and intensity of papules in LyP are 
decreased by rf FN-y administration. done intravenously in cases 1 and 4 and 
locally in case 5. 
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Figure 3. Treatment with rlFN-y decreases the 11ll1l1ber of CD30 + 
cells in the lesion. Immunohistochemical staining for CD3 (lI,r) and CD30 
(b,d) in the lesional slcin of case 4 before (a ,b) and aftcr (e, d) rlFN-y 
treatment shows a marked decrease in the number of infiltrating cell s. The 
effect of rlFN-y is 111 0re apparent on CD30 + ce ll s than on CD3 + cells. Senle 
{,,,r. 50 (J.m. 
exposure (Del Prete e/ Il l , 1995). Activated CD8 + T - cell clones 
producing T h2 cytokines express membrane CD30 and release 
soluble CD30, w hereas classic T h l-like CDS -' T-cell clones do not 
(M anetti c/ Ill. 1994). T h2 cytokine mRNA expression of CD30+ 
atypical cells in KiL an d LyP seems to be in accordance widl these 
fi ndings. Consistent with a previous observation (Vowels et Ill , 
1994) , normal d ermis con ta ined mRNA for both lL-2 and IFN-y, 
but not fo r "IL-4 or IL-5 m essage. Because no known end ogenous 
dermal cells produce IL- 2 and J FN- y, it is suggested that a small 
number of skin-infiltrating, activated T cells a re primed to produce 
small amou nts of these cytokines (Bos et Ill , 1987; Vowels e/ 11/, 
1994) . A ltho ugh the exact source was un kn own, IL-10 m essage 
detected in some of our samples might be derived from epithelial 
cells of hair fo llicl es and sweat glands left in the de rmis (Enk and 
Katz, 1992) . 
T he presence of mRNA for IL-2 and IFN- y in addition to Th2 
cytokines in cases 2 and 4 raises severa l poss ibilities with regard to 
th e cellular origin of these T h1 cytokines. Whereas skin-infil trating 
cells excl usive ly expressed CD30 and the fi:equency of nontl.lmor-
OllS inflammatory cells was low o r absent compared w ith tha t of 
atyp ica l cells, a subset of inflammatory cells might produce Thl 
cytokines. Likewise, it is probable that mRN A for Thl cytokines 
was expressed by dermal sessile components under pathologic 
condi tions. In case 4 , the fll1ding that upregula tion of mRNA 
expression for IL-2 and [FN-y was associated w ith disappearance of 
CD30 + cells favors th e cited possibilities and argues against the 
possibility that atyp ical ce lls produce Thl cytokines. In case 2, 
because of the lack of responsiveness to rIFN-y, we also should 
assume that mRNAs for Thl cytokines originated £i:om CD30+ 
cells; the tumor was harbored by one population tha t transcribed 
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both T hl and T h2 cytokine mH..NA or two populations that 
produced either T h l or T h2 cytokines. T he fact that lesio nal 
injection of rlFN-y did not downregul ate mRNA express ion for 
T h 2 cytokines seems to refute the latte r poss ibil ity. Ifboth types of 
cytokin es were produ ced by one popu lation, then CD30 + cells 
were the tumorous cO l1n terpa rt of ThO cells. In any event, it is 
highly Likely that CD30 ·' anaplastic ce ll s are the source of T h2 
cytok.lll e messages. 
T h e therapeutic efti cacy of rI FN- y for prim ary Cl1tan eous C D30 e 
lYlnphoproliferative disorders was ex amill ed ill two patients w ith 
KiL and two w ith LyP. Altho ugh the protocol was not do uble-blind 
or p l acebo-contro ll ed, this preliminary study suggested that three 
of four cases respo nded well to rlFN-y therapy. In cases 1 and 2, 
tbe skin lesions had been progress ive from the beginning of the 
disease, w ith 11 0 tendency toward spontaneous regress ion. In LyP 
(cases 4 and 5) , eruptions were waxing and wan ing before the 
treatn,.ent. To evalu ate o bjective ly the effect of rI FN-y, we com-
pared the tumor volume in KiL and scoring of eruptions in LyP 
before and afte r the treatment. Apparent o bjective improvement 
was noted in the respondin g patients. Furthermore, eruptions 
recurre d within several weeks after discontinuation of rI FN -y in 
these patien ts. Based on these resul ts, we believe tha t the improve-
ment "Was bro ught about by th e treatment. Patien ts with K iL have 
been treated with loca l excisio n, radiotherapy, and systemic poly-
chelnotherapy, and patients w ith LyP sho w a partial response to 
psoralen plu s UVA, topica l mechl ore thamine, and low doses of 
methotrexate (W ill em ze and Beljaards, 1993). Beca use most KiL 
has b een reported to ha ve a fa vorable prognosis and there is no 
satisfactory b·eatment for LyP, the administration of bio logic re-
sponse modifie rs such as IFN-y is the therapeutic choice fo r this 
recal citrant g roup of cutaneous lymphoma, especiall y in aged 
patients. T he mechanism b)' w hich IFN-y inhibi ts the prolife ra tio n 
of CD30 + cells, although currently speculative, may in volve the 
cooperative efFects of two r1 FN-y actions. O ne action is direct, in 
which rlFN-y dowllregula tes the transcription of cytokine mRNA 
by CD30+ cells and, by doing so, as observed in cases I , 4 , and 5, 
inhibits the pro li feration of these cells. In an indirect actio n, r1 FN- y 
enhances mRN A transc rip tion in in Aammatory Thl ce lls, as illus-
tra ted b y case 4, and these activated T h ·1 cells ma)' exert anti-tumor 
cell activity. 
CTCL is heterogeneo us w ith respect to mR.NA transcrip tio n and 
tbe p ,-odu ction of cytbkines. Both T hl- and T h2-type lymphoma 
cells arc reported in Sezary syn dro me and mycos is fungoides 
(Vowels el nl, 1992, 1994; Borish et nl, 1993; Saed ct nl, 1994; 
Tendler et nl, 1994; R ook c; nl, t 995; Vagi et nl, 1996). In Sezar), 
syndrome, in which tumor ce lls be long to the Th2 type (Vowels et 
ai, 1992, 1994; Borish ct n1, 1993; Sacd et (/1, ·1994; Tendl er ei ri 1, 
1994; Rook cf 111, ·1995), periph eral blood mo nonuclear ce lls 
manifest a defect in production of IL-1 2 (Rook ef 111, 1995), w hich 
is a potent inducer of lFN- y production (Chan cf 111, 199 1) and ThO! 
cells (Sypek et 111, 1993) . T he abnorma l cytokine profi le in these 
patients can be f.1Vorably alte red by IL-1 2 (Rook ef nl, 1995) . In 
mycosis fun goides, T h2 cytokine mRNA is detected in skin lesions 
at aU stages of the disease, frol11 the patch stage thro ugh the tumor 
I stage (Vowels CI 111, 1994). T hese o bservations suggest a poss ible I strategy for the treatm cnt of T h2-type CTCL w ith T hl cell-
I inducing moda li ties. In a recent phase II study in the U ni tcd States, some patients with Sezary syndrome responded filvorably to IFN- y (Kaplan ef 111, 1990). Furthermore, I FN-a , w hich also enhances T hl responses (Brin kmann ct (/ /, ·1993), is extreme ly eftective in the l treatment of some CTCL (O lsen 1'1 111, ·1989). On the other hand, 
we reported a case ofSezar), syndrome with a Thl cytokine profil e 
(Yagi e f 111, 1996) in w hich peripheral blood monon uclear ce lls 
transcribed mRN A on ly for IL-2 and IFN-I' and prod uced these 
~ cytokines , but not IL-4, upon stim ulati on . Others ha ve detected a 
Th 1 cytokine profile at th e plaque stage of m ycosis fungoides (Saed 
e/ nl, 1994). For T hI - type CTCL, treatm ent with I FN-y lIlay not be 
etfective but rather may lead to detel-io ratioll because of stimulation 
of tUlnor cells. In this study, we examin ed the e ffects of les ionally 
injected r1FN-y on atypica l ce lls at the cyto logic and genetic levels 
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before the therapeutic tria l. T his skill test was safe and provided 
important in formation o n predicting the effectiveness of rlFN- y. 
T herefore, before rl FN- y treatment, a predictive skin test in terms 
of the cytokill e profi le is needed in addition to categorization of 
cutaneous lymphoma. 
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